COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.
Malin HultcrantzJoshua RichterCara A RosenbaumDhwani PatelEric L SmithNeha KordeSydney X LuSham MailankodyUrvi A ShahAlexander M LesokhinHani HassounCarlyn TanFrancesco MauraAndriy DerkachBenjamin T DiamondAdriana RossiRoger N PearseDeepu MadduriAjai ChariDavid KaminetzkyMarc J BraunsteinChristian GordilloRan ReshefYing TaurFaith E DaviesSundar JagannathRuben NiesvizkySuzanne LentzschGareth J MorganOla LandgrenPublished in: Blood cancer discovery (2020)
Patients with multiple myeloma are immunocompromised, raising the question whether they are at higher risk of severe COVID-19 disease. In this large case series on COVID-19 in patients with multiple myeloma, we report 29% mortality rates among hospitalized patients and identify race/ethnicity as the most significant risk factor for severe outcome.See related commentary by Munshi and Anderson, p. 218. This article is highlighted in the In This Issue feature, p. 215.